Biocytogen Pharmaceuticals (Beijing) Co., Ltd. have announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.
Biocytogen will use their proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMice™ (RenMab™ and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
